PA007175: Recombinant Anti-HIV gp120-gp41 Interface Human IgG1 Kappa Monoclonal Antibody (Clone PGT151), In Vivo Grade

Catalog No.: PA007175 | **Product Name:** In Vivo Grade Recombinant Anti-HIV gp120-gp41 Interface Monoclonal Antibody (Clone PGT151), Human IgG1 Kappa

The research grade anti-HIV gp120-gp41 interface monoclonal antibody (clone PGT151) is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

PRODUCT SPECIFICATIONS

Catalog No.	PA007175
Product Name	In Vivo Grade Recombinant Anti-HIV gp120-gp41 Interface Monoclonal Antibody (Clone PGT151), Human IgG1 Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Summary	The in vivo grade recombinant anti-HIV gp120-gp41 interface human IgG1 monoclonal antibody was produced in mammalian cells.
Clone	PGT151.
Isotype	human IgG1, kappa.
Specificity/Sensitivity	HIV gp120-gp41 interface.
Applications	ELISA, Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping & Storage	The in vivo grade recombinant anti-HIV gp120-gp41 interface antibody (clone of PGT151) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.

REFERENCES & BACKGROUND

The in vivo grade recombinant anti-HIV gp120-gp41 interface human IgG1 monoclonal antibody was produced in mammalian cells.

Clone PGT151 is a broadly neutralizing antibody that binds to a cleavage-dependent, tri-glycan-dependent epitope at the interface between gp120 and gp41 subunits of the HIV-1 envelope trimer, serving as an indispensable reagent for structural analysis, trimer stability testing, and viral entry inhibition studies.